– USA, NY – Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced the nominations of Sir Michael Rawlins for the election to its board as a new independent director at its 2021 AGM, scheduled for June 21, 2021.
Concurrently, Joel Marcus is being nominated for re-election to the board.
“We are excited to announce the nomination of Sir Michael Rawlins as we look forward to the potential approval of CAPLYTA for bipolar depression and the Company’s continued growth,” said Chairman and CEO,Dr. Sharon Mates. “Sir Michael’s extensive regulatory experience and product development expertise will be beneficial to the Company as we execute on our strategies for future growth. We are also grateful to Joel Marcus for his continued service and the strong leadership he provides.”
Additionally, the Company also announced that effective as of 2021 AGM, Dr. Christopher Alafi will have completed his term as a board member and will no longer serve as a director for the Company.
About Sir Michael Rawlins
Sir Michael was the chairman of the Medicines and Healthcare products Regulatory Agency from 2014 to 2020. He previously served on the Company’s board from 2013 to 2014 until he was required to resign under MHRA independence policies in connection with assuming his leadership role in 2014. He is a clinical pharmacologist and specialist in internal medicine. He was the chair of the National Institute for Health and Care Excellence from 1999 to 2013. He was a professor of clinical pharmacology in Newcastle, United Kingdom, and physician at the Newcastle Hospitals, from 1999 to 2006. He was chairman of the Committee on Safety of Medicines (1992-1998), chairman of the Advisory Council on the Misuse of Drugs (1998-2008), and founding chairman of the National Institute for Clinical Excellence (1999-2013). He is a past president of the Royal Society of Medicine (2012-2014). Currently, Sir Michael is an honorary professor at the London School of Hygiene and Tropical Medicine, and an emeritus professor at the University of Newcastle upon Tyne. Sir Michael was appointed Knight Grand Cross of the Order of the British Empire in 2017. The honor is for services to the safety of medicines, healthcare, and innovation and comes after more than three decades at the forefront of innovation, development, and leadership in the public health sector.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.
For more information: https://www.intracellulartherapies.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.